RxDoctor Payments Data

Jude Espinoza, MD

Cardiovascular Disease · San Antonio, TXNPI 1124027743

Payments from drug & device makers

$5,316in general payments, 2019–2025

Across 317 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Novartis$927
  • Johnson & Johnson$811
  • Merck$320
  • Pfizer$246
  • Scpharmaceuticals Inc.$193
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,28399%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,316 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$137,184
Medicare patients
596
Services billed
1,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$217,812
EntrestoSacubitril/Valsartan141$155,781
XareltoRivaroxaban44$57,777
JardianceEmpagliflozin40$36,871
FarxigaDapagliflozin Propanediol20$22,997
Repatha SyringeEvolocumab15$9,271
Nebivolol Hcl101$4,821
Hydralazine Hcl346$4,816
Losartan Potassium328$3,462
Metoprolol Succinate166$2,811
Nifedipine ErNifedipine78$2,642
Ranolazine ErRanolazine25$2,352
Valsartan64$2,177
Amlodipine Besylate362$2,059
Carvedilol268$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$246$217,812224 claims
NovartisEntresto$927$155,781141 claims
Johnson & JohnsonXarelto$811$57,77744 claims
Boehringer IngelheimJardiance$168$36,87140 claims
AstraZenecaFarxiga$19$22,99720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →